Andres Wiernik

582 total citations
8 papers, 461 citations indexed

About

Andres Wiernik is a scholar working on Immunology, Hematology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Andres Wiernik has authored 8 papers receiving a total of 461 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Immunology, 3 papers in Hematology and 2 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Andres Wiernik's work include Immune Cell Function and Interaction (4 papers), T-cell and B-cell Immunology (3 papers) and Hematopoietic Stem Cell Transplantation (2 papers). Andres Wiernik is often cited by papers focused on Immune Cell Function and Interaction (4 papers), T-cell and B-cell Immunology (3 papers) and Hematopoietic Stem Cell Transplantation (2 papers). Andres Wiernik collaborates with scholars based in United States and Australia. Andres Wiernik's co-authors include Daniel A. Vallera, Jeffrey S. Miller, Michelle Gleason, Erica D. Warlick, Julie A. Ross, Michael R. Verneris, Daniel J. Weisdorf, Xianghua Luo, Bruce Walcheck and Bin Zhang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Andres Wiernik

8 papers receiving 455 citations

Peers

Andres Wiernik

IMMUN

ONCOL

HEMAT

MB

EDM

Zhihua Tian China

Tanja Telieps Germany

Stefania Laurent Italy

Maged S. Mahmoud Japan

Manfred Smetak Germany

Sine Reker Denmark

StevenA. Rosenberg United States

Oliver Eltherington United Kingdom

Asaka Kondo Japan

Nishta Ramnoruth Australia

Zhihua Tian China

Andres Wiernik

280 ×0.8

IMMUN

107 ×0.4

ONCOL

169 ×1.4

HEMAT

40 ×0.7

MB

7 ×0.1

EDM

Citations per year, relative to Andres Wiernik Andres Wiernik (= 1×) peers Zhihua Tian

Countries citing papers authored by Andres Wiernik

Since Specialization

Citations

This map shows the geographic impact of Andres Wiernik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andres Wiernik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andres Wiernik more than expected).

Fields of papers citing papers by Andres Wiernik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andres Wiernik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andres Wiernik. The network helps show where Andres Wiernik may publish in the future.

Co-authorship network of co-authors of Andres Wiernik

This figure shows the co-authorship network connecting the top 25 collaborators of Andres Wiernik. A scholar is included among the top collaborators of Andres Wiernik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andres Wiernik. Andres Wiernik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Touma, Waseem, et al.. (2017). Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection. Journal of Clinical Neuroscience. 41. 75–77. 50 indexed citations

2.

Guinness, Joseph, et al.. (2017). Clinical implications of the 2012 US Preventive Services Task Force (USPSTF) PSA screening recommendation in prostate cancer diagnoses and 5-year survival at a Minnesota safety net health care system.. Journal of Clinical Oncology. 35(15_suppl). 5051–5051. 2 indexed citations

3.

Ries, Michael, et al.. (2015). Health disparities in advance care planning at a safety-net hospital.. Journal of Clinical Oncology. 33(29_suppl). 125–125. 2 indexed citations

4.

Gleason, Michelle, Julie A. Ross, Erica D. Warlick, et al.. (2014). CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood. 123(19). 3016–3026. 208 indexed citations

5.

Wiernik, Andres, Bree Foley, Bin Zhang, et al.. (2013). Targeting Natural Killer Cells to Acute Myeloid LeukemiaIn Vitrowith a CD16 × 33 Bispecific Killer Cell Engager and ADAM17 Inhibition. Clinical Cancer Research. 19(14). 3844–3855. 176 indexed citations

6.

Wiernik, Andres, et al.. (2012). Occult Primary Medullary Thyroid Carcinoma Presenting with Pituitary and Parotid Metastases: Case Report and Review of the Literature. Endocrine Pathology. 23(2). 115–122. 9 indexed citations

7.

Wiernik, Andres, Bree Foley, Bin Zhang, et al.. (2012). Bi-Specific Killer Cell Engagers (BiKEs) Signaling Through CD16 and Targeting CD33 (CD16 × CD33), Triggers Natural Killer (NK) Cell Cytotoxic and Cytokine Production Against Refractory Acute Myeloid Leukemia (AML). Blood. 120(21). 256–256. 1 indexed citations

8.

Pegram, Hollie J., David Ritchie, Mark J. Smyth, et al.. (2010). Alloreactive natural killer cells in hematopoietic stem cell transplantation. Leukemia Research. 35(1). 14–21. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact